LEADER 02435nam 22005893u 450 001 9910465161203321 005 20210114104910.0 010 $a1-78084-189-2 035 $a(CKB)2560000000152109 035 $a(EBL)1179648 035 $a(SSID)ssj0001599933 035 $a(PQKBManifestationID)16306834 035 $a(PQKBTitleCode)TC0001599933 035 $a(PQKBWorkID)14892902 035 $a(PQKB)10768650 035 $a(MiAaPQ)EBC1179648 035 $a(Au-PeEL)EBL1179648 035 $a(OCoLC)877767242 035 $a(EXLCZ)992560000000152109 100 $a20140421d2013|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aGout$b[electronic resource] 205 $a1st ed. 210 $aLondon $cFuture Medicine Ltd$d2013 215 $a1 online resource (246 p.) 300 $aDescription based upon print version of record. 311 $a1-78084-191-4 327 $aTitle page; Copyright page; Contents; Foreword. Gout; 1. Epidemiology of gout; 2. Pathological basis of hyperuricemia and gout; 3. Pathophysiology and immunology of acute and chronic gout; 4. An update on the genetic causes of hyperuricemia and gout; 5. Clinical features of gout; 6. Synovial fluid analysis and crystal identification; 7. Imaging of gout; 8. Outcome measures in gout; 9. The patient's perspective of gout; 10. Asymptomatic hyperuricemia and its clinical implications for extra-articular disease; 11. Principles of gout management 327 $a12. Urate-lowering therapy: xanthine oxidase inhibitors13. Urate-lowering therapy: uricosurics; 14. Urate-lowering therapy: uricases; 15. Therapies for acute flares and gout flare prophylaxis; 16. Gout comorbidities: prevalence and management; 17. Emerging therapeutics for acute and chronic gout; Index 330 $aGout 606 $aGout 606 $aMusculoskeletal system -- Diseases 606 $aMusculoskeletal system 608 $aElectronic books. 615 4$aGout. 615 4$aMusculoskeletal system -- Diseases. 615 4$aMusculoskeletal system. 676 $a616.3/999 700 $aDalbeth$b Nicola$0908608 701 $aPerez-Ruiz$b Fernando$0755333 701 $aSchlesinger$b Naomi$0939598 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910465161203321 996 $aGout$92472001 997 $aUNINA